Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 25, 2026DrugsOpen Access

Autoimmune Bullous Diseases: Therapeutic Update

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMichael KasperkiewiczNBN. van BeekESEnno Schmidt

Discussion

Loading...

Member takes

Overview

Review summarizes recent clinical trials and new therapies for autoimmune blistering diseases, indicating a need for effective treatments.

Key Points

  • This review aims to summarize recent advancements and current treatment options for autoimmune blistering diseases (AIBDs).
  • Review of randomized controlled trials (RCTs) for pemphigus and bullous pemphigoid.
  • Analysis of new therapeutic agents like dupilumab and efgartigimod.
  • Overview of national and international treatment guidelines.
  • Recent approval of dupilumab for bullous pemphigoid signifies treatment progress.
  • Immunoadsorption and rilzabrutinib show promise for pemphigus.
  • Lack of RCTs for mucous membrane pemphigoid highlights unmet medical needs.

Cite This Study

Kasperkiewicz et al. (2026) studied this question.

synapsesocial.com/papers/699e918df5123be5ed04f25fhttps://doi.org/10.1007/s40265-026-02292-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris2024 · 9 citations
  2. 2Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure2024 · 53 citations
  3. 3Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria2022 · 134 citations
  4. 4Pentoxifylline (Anti-Tumor Necrosis Factor Drug): Effective Adjuvant Therapy in the Control of Ocular Cicatricial Pemphigoid2011 · 27 citations
  5. 5Anti‐interleukin‐ 17A biologics for the long‐term treatment of bullous pemphigoid: A prospective, cohort study2023 · 4 citations